lapatinib has been researched along with sf 1126 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (sf 1126) | Trials (sf 1126) | Recent Studies (post-2010) (sf 1126) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 15 | 2 | 13 |
| Protein | Taxonomy | lapatinib (IC50) | sf 1126 (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 5.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Durden, DL; Garlich, JR; Morales, GA; Newblom, J; Peng, X; Su, J; Weber, K | 1 |
1 other study(ies) available for lapatinib and sf 1126
| Article | Year |
|---|---|
Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; Chromones; Enzyme Inhibitors; Humans; MCF-7 Cells; Morpholines; Neoplastic Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Structure-Activity Relationship; Thiophenes | 2013 |